The expiration of the patent for semaglutide held by Novo Nordisk in India could transform the market for treatments against diabetes and obesity, by promoting the arrival of more accessible generic versions.
This active ingredient, used in popular weight loss and diabetes treatment medications, will now be able to be produced by Indian laboratories, paving the way for a significant price reduction.
This development could allow more patients to access these treatments, in a country where the prevalence of diabetes and obesity is rising sharply.
Local manufacturers are already preparing to launch their own versions of the drug, which is expected to intensify competition in a rapidly expanding market.
However, this democratization also raises concerns. Some experts fear misuse or unregulated use of these treatments, particularly due to sometimes uneven medical monitoring depending on the region.
Health authorities will therefore have to find a balance between improving access to care and the need to guarantee safe and controlled use of these medicines.
This turning point illustrates the major impact of the end of pharmaceutical patents on emerging markets, where the arrival of generics can profoundly alter access to treatments and the dynamics of the sector.
Community
Comments
Comments are open, but protected against spam. Initial posts and comments containing links undergo manual review.
Be the first to comment on this article.